Session Three: C-Peptide and Clinical Benefits in T1D
A Talk by Prof. Helen Colhoun , Prof. Colin Mark Dayan and Kimberly Collins
About this Talk
In the final two sessions of the workshop, we will focus on the question of C-peptide’s relationship to clinical benefit, its potential context of use and comparison to HbA1c, and how the use of C-peptide as an endpoint could accelerate the development of disease-modifying therapies for T1D.
- Topic One: C-Peptide and Long-Term Benefits
- Topic Two: C-Peptide and Near-Term Benefits
- Topic Three: Modeling of C-Peptide and Its Relationship to HbA1c